Your session is about to expire
← Back to Search
Chemotherapy for Pancreatic Cancer
Study Summary
This trial looks at giving capecitabine & temozolomide after surgery to patients with a certain kind of pancreatic tumor. These drugs work in different ways to stop the growth of tumor cells. This could prevent or delay the return of cancer in these patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 & 3 trial • 151 Patients • NCT03093870Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have cancer spread to my brain or its coverings.I have no allergies to medications similar to temozolomide or capecitabine.I do not have problems absorbing medications.I am not planning to take warfarin during the treatment.I have had bleeding in my stomach or intestines.I do not have any ongoing or uncontrolled infections.Participants must have specific levels of blood cells and chemicals in their blood.I do not have untreated metastatic cancer.I have not had pre-surgery treatment for pancreatic neuroendocrine tumor, but may have used somatostatin analogs.I've had a recent scan showing no signs of cancer spread.I have no other active cancers or a history of cancer, except for certain exceptions.I have a blockage in my digestive tract.I am 18 years old or older.I have not had a heart attack or stroke in the last year.My surgery removed all visible cancer, or nearly all.I've had a full medical check-up in the last 28 days.If you have pancreatic neuroendocrine tumors that have been surgically removed, you need to have a Zaidi score of 3 or higher based on certain factors and points.I have recovered from any surgery effects, as confirmed by my doctor.I had surgery or ablation for up to 5 liver metastases during my pancreatic NET surgery.I can take care of myself and am up and about more than 50% of my waking hours.I can swallow pills.My Ki-67 test result is between 3% and 55%, done within the last 14 to 90 days.I can undergo CT or MR imaging with contrast agents as needed.I experienced pain from my tumor before it was surgically removed.My tumor causes symptoms.I haven't taken somatostatin analogs after my surgery.I had surgery to remove a well-differentiated pancreatic tumor between 14 and 90 days ago.
- Group 1: Arm I (capecitabine, temozolomide)
- Group 2: Arm II (surveillance)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available slots for new patients in this research project?
"This study is currently recruiting participants, as indicated on clinicaltrials.gov. The trial was originally posted on October 14th, 2021 and was last updated on December 3rd, 2021."
Are there potentially fatal side effects to taking Capecitabine?
"While there is some data suggesting capecitabine is safe, as this is only a Phase 2 trial, there is no clinical evidence yet to support its efficacy. Consequently, it received a score of 2."
What are some other research projects that have used Capecitabine?
"As of now, there are 561 total trials regarding Capecitabine with 153 being in the third stage. Although many studies for this treatment are based in Woolloongabba, Queensland, there are a whopping 16764 locations running clinical trials for it."
How many people can join this research project?
"That is correct. The clinical trial, which began recruitment on October 14th 2021, is still looking for patients. There have been no changes to the 6 participating sites or the 141 patient goal since December 3rd 2021."
For what purpose is Capecitabine most often prescribed?
"Capecitabine is a medication that can be used to manage progression, disease. It has also been shown to help patients with nitrosourea treatment, advance directives, and refractory, advanced mycosis fungoides."
Is this an innovative clinical trial?
"There are 561 ongoing studies for the medication Capecitabine in 70 different countries. The first study was held 18 years ago and involved 60 patients. It completed Phase 2 of testing in 2002 and was sponsored by Schering-Plough. Since that time, 843 total studies have been completed."
At how many hospitals is this research being conducted?
"There are six medical centers participating in this study, located in Ames, Fort Dodge, Boone, and other cities."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger